BP8039 Advanced Glycation End Products (AGE) antibody
see related secondary antibodiessee all 2 Advanced Glycation End Products products
0.2 mg / US$ 515
NOVUS BIOLOGICALS
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
Quick Overview
Rabbit anti Advanced Glycation End Products (AGE)
Synonyms
Advanced Glycation End Products, ,
Product review
Please read our product review about Advanced Glycation End Products (AGE): AGE – Advanced Glycation End Products.
Product Description
Rabbit anti Advanced Glycation End Products (AGE) , Presentation: Purified. Product is tested for Frozen sections ( C ), Enzyme Immunoassay ( E )
Properties
| Applications | Frozen sections ( C ), Enzyme Immunoassay ( E ) |
| Reactivity | Human ( Hu ) |
| Presentation | Purified |
| Host | Rabbit |
| Catalog Number | BP8039 |
| Swiss Prot. No. | Q15109 |
| Quantity | 0.2 mg |
| Price | US$ 515 |
| Delivery | Worldwide |
| Manufacturer | Acris Antibodies GmbH |
| Datasheet | view  BP8039.pdf |
Datasheet Extract
| Concentration | 1.0 mg/ml |
| Background | Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) Ã?2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimers disease. These results suggested the potential role of AGE in normal aging and age-enhanced disease processes. |
| Immunogen | Advanced Glycation End Products /BSA/HSA
Swiss Num.: Q15109 |
| Format | State: Liquid IgG fraction Purification: Protein A affinity chromatography BufferSystem: PBS, pH 7.3, 0.09% NaCl, containing 0.5% BSA and 0.09% sodium azide |
| Applications | This antibody is suitable for the detection of different AGE products in tissues, tissue extracts and body fluids.
ELISA (1-5 µg/ml, incubation time 18 hrs at 4°C) Immunohistochemistry (2-10 µg/ml, incubation time 60 min at RT or 18 hrs at 4°C). Positive control: human lens, arteriosclerotic plaques. |
| Specificity | Recognizes Advanced Glycation End Products (AGE), cross-reactivity with
BSA and HSA < 1%. Species: Human. |
| Storage | This antibody can be stored at 2-8°C for up to one month or in aliquots at -20°C for one year from despatch.
Avoid repeated freezing and thawing. |
| References | 1. Horiuchi S., Araki N., and Morino Y. (1991) Immunological approach to characterize advanced glycation end products of the Maillard reaction: Evidence for the presence of a common stucture. J. Biol. Chem. 266; 7329-7332.
2. Akari N., Ueno N., Chakrabarti B., Morino Y., and Horiuchi S. (1992) Immunochemical evidence of the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem. 267; 10211-10214. 3. Miyata T., Odo O., Inagi R., Iida Y., Araki N., Yamada N., Horiuchi S., Taniguchi N., Maeda, et al. (1993) ÿ2-Microglobulin modified with advanced glycation end products is a major component of haemodialysis-associated amyloidosis. J. Clin. Invest. 92; 1243-1252. 4. Kume S., Takeya M., Mori T., Araki N., Suzuki H., Horiuchi S., Kodama T., Miyauchi Y., and Takahashi K. (1995) Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta using a novel specific monoclonal antibody. Am J. Pathol. 147; 654-667. 5. Kimura T., Takamatsu J., Ikeda K., Kondo A., Miyakawa T., and Horiuchi S. (1996) Accumulation of advanced glycation end products of the Maillard reactionwith age in human hippocampal neurons. Neurosci. Lett. 208; 53-56. 6. Cellek S., Qu W., Schmidt A.M., and Moncada S. (2004) Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuron apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia 47; 331-339. |
12 Secondary Antibodies
| Catalog No. | Name / Host | Presentation | Reactivity | ||||
|---|---|---|---|---|---|---|---|
| R1364B | Rabbit IgG (H&L) | ||||||
| Goat | Biotin | 2 mg / US$ 295 | |||||
| R1364F | Rabbit IgG (H&L) | ||||||
| Goat | FITC | 2 mg / US$ 285 | |||||
| R1364T | Rabbit IgG (H&L) | ||||||
| Goat | TRITC | 2 mg / US$ 285 | |||||
| R1364TR | Rabbit IgG (H&L) | ||||||
| Goat | Texas Red | 2 mg / US$ 295 | |||||
| R1364HRP | Rabbit IgG (H&L) | ||||||
| Goat | HRP | 2 mg / US$ 295 | |||||
| R1364AP | Rabbit IgG (H&L) | ||||||
| Goat | AP | 1 mg / US$ 325 | |||||
| R1458C2 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy2 | 1 mg / US$ 445 | |||||
| R1458C3 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy3 | 1 mg / US$ 445 | |||||
| R1458C35 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy3.5 | 1 mg / US$ 445 | |||||
| R1458C5 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy5 | 1 mg / US$ 445 | |||||
| R1458C55 | Rabbit IgG (H&L) multi-species ads. | ||||||
| Goat | Cy5.5 | 1 mg / US$ 445 | |||||
| R1427R | Rabbit IgG (H&L) F(ab')2 Fragment multi-species ads. | ||||||
| Donkey | PE | 1 ml / US$ 455 | |||||
Click here to see all secondary antibodies for 'BP8039 Advanced Glycation End Products (AGE)'.
